ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
82.285
0.01%
Bitcoin
67,837.34
-0.47%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Spero Therapeutics Inc (SPRO)

  7. Spero Therapeutics Inc (SPRO) News

SPRO

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRO
DateTimeSourceHeadlineSymbolCompany
07/03/20241:05PMGlobeNewswire Inc.Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
06/03/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
05/30/20244:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
05/15/20244:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
05/15/20247:50AMIH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:SPROSpero Therapeutics Inc
03/06/20248:05AMGlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
02/28/20248:05AMGlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
02/26/20248:05AMGlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
02/09/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
02/05/20248:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/05/20248:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/05/20248:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/05/20248:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/05/20248:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
02/05/20244:50PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
01/31/20244:05PMGlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
01/08/20246:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
01/05/20248:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
01/05/20248:05AMGlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
01/04/20244:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
01/02/20248:13AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
01/02/20248:05AMGlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
11/15/20234:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
11/15/20234:15PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
11/13/20234:50PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
11/13/20234:45PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
11/13/20234:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
11/13/20234:05PMGlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
11/13/20234:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
11/13/20236:45AMIH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SPRO

Your Recent History

USOTC
BIEL
Bioelectronics (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
HIRU
Hiru (PK)
USOTC
SPZI
Spooz (PK)
USOTC
RONN
Ronn Motor (PK)
COIN
BTCUSD
Bitcoin
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
COOP
Mr Cooper
NASDAQ
LWLG
Lightwave Logic
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AMRN
Amarin
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
NSAV
Net Savings Link (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved